Last reviewed · How we verify
Docetaxol — Competitive Intelligence Brief
phase 2
Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Docetaxol (Docetaxol) — Fudan University.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Docetaxol TARGET | Docetaxol | Fudan University | phase 2 | Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor | ||
| Taxotere | Taxotere | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | marketed | Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Docetaxol — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing